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Objective: The management of pregnant women with diabetes mellitus places a significant burden on healthcare systems. Sig-
nificant global changes have been proposed with regard to the diagnosis and management of women with diabetes mellitus 
in pregnancy. The study aims were to document the contemporary numbers, treatments and outcomes of diabetes mellitus in 
pregnancy, with particular focus on gestational and type 2 diabetes mellitus.
Design, subjects and setting: A retrospective audit was performed of pregnant women (n = 278) with diabetes mellitus, man-
aged over a 12-month period in a combined secondary and tertiary unit in South Africa.
Results: Of the 278 cases analysed, 60% had gestational and 33% type 2 diabetes mellitus. The perinatal mortality ratio for all 
diabetes mellitus in pregnancy was 52.6:1 000, with only one early neonatal death. Ninety-five per cent and 70% of women with 
gestational and type 2 diabetes mellitus, respectively, were overweight or obese. Chronic hypertension was present in 23% of 
women with gestational and in 42% of women with type 2 diabetes mellitus. The glycosylated haemoglobin decreased from 6.7% 
at diagnosis to 6.4% at delivery in the gestational diabetes mellitus group, and from 7.5% at booking to 6.6% at delivery in the type 
2 diabetes mellitus subjects. Lifestyle modification and metformin sufficed in 88% of women with gestational diabetes mellitus. 
Insulin was only required in 12% of pregnancies with gestational and in 53% of pregnancies with type 2 diabetes mellitus.
Conclusion: Pregnancies complicated by gestational and type 2 diabetes mellitus are common and challenging. The addition of 
the oral agent, metformin, lowers the need for insulin therapy.
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Introduction
Glucose metabolism changes during pregnancy.  Compared to those 
in non-pregnant women, fasting levels of serum glucose are decreased, 
while postprandial levels are increased. Glucose tolerance decreases 
progressively after the first trimester. Physiological insulin resistance is 
brought about by placental hormones, such as human placental 
lactogen, glucagon and cortisol. Ultimately, insulin production is 
almost doubled to maintain euglycaemia. This explains gestational 
diabetes mellitus when the increased demand for insulin is not met 
owing to a genetically programmed reduced β-cell reserve, as well as 
the increased therapy requirements of established diabetes mellitus.
The incidence of type 2 and gestational diabetes mellitus is 
rising. Firstly, populations are becoming older and obese. Rising 
levels of obesity, corresponding with high-calorie diets and 
decreased physical activity, affect many countries, including 
South Africa.1,2 Secondly, diagnostic thresholds have been 
lowered in gestational diabetes mellitus, following the sentinel 
Hyperglycemia and Adverse Pregnancy Outcome (HAPO)3,4 and 
Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS)5 studies, which showed composite benefit by beginning 
an intervention at a lower glucose level.
The diagnosis and management of diabetes mellitus in pregnancy 
continues to change, but currently still lacks universal agreement. 
Specific screening and diagnostic tests with a threshold should 
reflect an equitable balance between current and future health 
risks and local resource capacity, but practice is inconsistent, even 
in countries with stipulated screening policies.6 The cost, time and 
reliability factors of screening and diagnostic tests present 
challenges at all levels. Regarding medical interventions, two oral 
agents, i.e. metformin and glibenclamide or glyburide, have been 
integrated into certain treatment regimens during pregnancy.7,8
The aims of this study were to document the contemporary 
numbers, treatments and outcomes of pregnant patients with 
diabetes mellitus in a combined secondary or tertiary unit, with 
particular focus on gestational and type 2 diabetes mellitus, 
because of the changes in diagnosis and management.
Method
A retrospective audit of pregnant women with diabetes mellitus 
managed from 1 July 2010 to 31 June 2011 was performed. The 
audit was conducted in the Obstetric Special Care Unit at Tyger-
berg Academic Hospital, a secondary and tertiary hospital in 
South Africa. Patients were managed by a team of  obstetricians, 
endocrinologists and dietitians. The files of all registered cases 
were assessed. Data were captured anonymously.
A diagnosis of pre-gestational diabetes mellitus (types 1 or 2) 
was made when the history was known. Gestational diabetes 
mellitus was regarded as any new-onset dysglycaemia in preg-
nancy in this study. It was diagnosed according to the provincial 
guideline on diabetes mellitus in pregnancy, which advocates a 
selective rather than universal approach to screening.9 Patients 
with risk factors are tested between 24 and 28 weeks’ gestation, 
or earlier, if necessary. The guideline provides two options for 
testing. The first is a 75 g oral glucose tolerance test (OGTT) with 
fasting and two-hour blood glucose sampling. A glucose load of 
75 g is substituted by a non-standardised glycaemic load in the 
second practical option, whereby the patient’s breakfast is 
brought to the clinic and consumed after the fasting glucose 
test. A two-hour postprandial blood glucose measurement is 
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then performed. Both options use cut-off values of 5.6 mmol/l 
and 7.8 mmol/l, for the fasting and two-hour values, respectively.9 
The second option was followed during this study. Glucose levels 
were measured using capillary samples for the Accu-Chek® Active 
glucometer, which corrects to venous sample values.
Upon clinic entry, patients with pre-gestational diabetes mellitus 
underwent special investigations and a review of their history and 
an examination. Serum creatinine, urinary protein quantification 
and culture were performed. The haemoglobin (Hb)A1c level was 
determined (a target threshold of 6%) and repeated monthly 
thereafter. A formal ophthalmological evaluation was carried out 
to exclude pathology. Foetal evaluation included an 11–13 week 
scan, followed by a detailed scan at 18–22 weeks, umbilical artery 
Doppler at 24 weeks, and a growth scan between 34 and 36 weeks’ 
gestation. Similar investigations were performed for patients with 
gestational diabetes mellitus.
Patients with gestational diabetes mellitus were managed according 
to the provincial guideline, beginning with lifestyle modification 
(diet and moderate exercise). When this failed to lower fasting, 
postprandial and HbA1c levels to the target threshold, oral therapy 
with metformin was instituted at 500 mg twice daily with meals, and 
increased incrementally to 850  mg three times daily with meals. 
When glycaemic control was still insufficient, patients were 
admitted to evaluate fasting and all pre- and two-hour postprandial 
values, including a 02h00 value in order to commence insulin 
therapy. Target levels used were 3.5–5.5 mmol/l (fasting),< 7 mmol/l 
(two-hour postprandial) and  <  6.1% for the HbA1c. Foetal 
macrosomia and polyhydramnios were also regarded as evidence of 
suboptimal control.
Oral sulphonylureas were stopped in pre-gestational type 2 diabetes 
mellitus, but metformin was continued or started. Lifestyle 
modifications and medical therapy were re-evaluated every two 
weeks. When insulin was required, it was initiated using a nocturnal 
dose of intermediate-acting human neutral protamine hagedorn 
insulin to optimise fasting glucose values before consideration was 
given to a multiple injection regimen (basal bolus regimen). 
Thereafter, preprandial doses of short-acting insulin (human regular 
insulin) were added, as necessary. Patients receiving daily or bi-daily 
doses of fixed-combination insulin (human 30/70 biphasic insulin) 
before pregnancy continued with their regimen, provided that 
control was optimal. A basal bolus regimen was initiated when 
necessary and feasible.
Pregnant women with diabetes mellitus were seen in the obstetric 
special care clinic every two weeks, when a glucose profile was 
performed. Patients on insulin used Accu-Chek Active® glucometers 
to monitor their glucose profiles at home. These were recorded on 
a provided chart and reviewed regularly.
Delivery was offered as standard practice at 38 weeks’ gestation. 
Intrauterine death was defined as asystole after 24 weeks’ gestation 
or > 500 g at birth. Viability was defined as 27 weeks’ gestation or an 
estimated foetal weight ≥ 800 g. Other important definitions were 
macrosomia, i.e. a birthweight  >  4 000  g or characteristic 
ultrasound findings; neonatal hypoglycaemia, i.e. a glucose value 
of < 2.6 mmol/l or symptomatic hypoglycaemia; and early neonatal 
death, i.e. death within the first six days of life.
Data were analysed using Statistica® version 9 and largely 
expressed as medians, ranges or n (%). Differences were analysed 
using Student’s t-test. The Mann-Whitney U test was used for data 
that was not normally distributed. Analysis of variance or the 
Kruskal-Wallis test was applied for comparisons between 
continuous variables and nominal variables, while the chi-square 
test (Fisher’s method) was used to compare two nominal 
variables. A p-value of  <  0.05 was regarded as significant. The 
study was approved by the Ethics Committee for Human Research 
of the Faculty of Medicine and Health Sciences, Stellenbosch 
University (N11/09/268).
Results
Three hundred and one patients were entered during the 
12-month period. Twenty-three files were excluded because of 
incorrect diagnosis or classification, leaving 19 (6.8%) patients 
with pre-gestational type 1 diabetes mellitus, 92 (33.1%) patients 
with pre-gestational type 2 diabetes mellitus, and 167 (60.1%) 
patients with gestational diabetes mellitus for class data analysis. 
During the study period, there were 5 430 hospital births, with 
266 deliveries by patients with diabetes mellitus after the 
exclusion of miscarriages. Therefore, the deliveries of patients 
with diabetes mellitus constituted 4.9% of the referral hospital 
deliveries. Neonatal data from five multiple pregnancies were 
incomplete. The perinatal mortality rate was 52.6/1 000. The 
baseline characteristics are shown in Table 1.
Gestational diabetes mellitus
A normal body mass index (BMI) at booking was recorded in 9 (5.4%) 
of the women with gestational diabetes mellitus. Twenty-four 
(14.4%) were overweight, 69 (41.3%) obese (a BMI of 30–39 kg/m2), 
and 65 (38.9%) morbidly obese (a BMI of ≥ 40 kg/m2). The median 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) at 
booking was 130 mmHg (83–190 mmHg) and 78 mmHg (57–120 
mmHg), respectively. Of the 38 (22.8%) women with chronic 
hypertension, 20 (52.5%) were not taking antihypertensive 
treatment. Other baseline values (median or range) were daily 
urinary protein excretion of 200 mg (100–2 500 mg) and serum 
creatinine of 51 μmol/l (20–90 μmol/l).
The median first HbA1c value was 6.7% (4.8–12%). The 25
th and 
75th percentiles were 5.9% and 7.4%, respectively. The median 
pre-delivery HbA1c lowered to 6.4% (4.4–11.7%). The 25
th and 75th 
percentiles were 5.9% and 6.9%, respectively. The final treatment 
modalities are shown in Table 2.
Important maternal complications according to the mean HbA1c 
category are shown in Table 3. An association was not demon-
strated between metformin use and spontaneous preterm labour 
(p 0.1). Two intrauterine deaths occurred in this group. The first 
was diagnosed at 40 weeks’ gestation and weighed 3 040 g. The 
mother had defaulted on attending appointments and had given 
a history of reduced foetal movement. In the second case, the 
patient presented with early pre-eclampsia and an intrauterine 
death at gestation of 32 weeks, 6 days. The baby weighed 1 770 g.
Most deliveries (n = 93, 55.7%) occurred at 38  weeks’ gestation. 
There were 54 (32.3%) deliveries before, and 19 (11.4%) beyond, 
38 weeks’ gestation. Eighty-eight patients (53%) were delivered by 
Caesarean section. Of these, 34 were elective procedures, 51 
non-elective procedures, while the indication was unclear in three 
cases. Foetal macrosomia was suspected in 10 of the 
elective Caesarean sections. Thirty-two of the non-elective 
procedures were performed after induction of labour. Only 19 were 
regarded as emergency procedures. The median (range) gestation 
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at delivery was 38 weeks (31–41 weeks) and the median birth-
weight 3 280 g (1 570–5 101 g). A birthweight of > 4 kg was recorded 
in 28 (17.4%) babies. There was one case of shoulder dystocia. A 
five-minute Apgar score < 7 was recorded for six babies, and two 






Gestational diabetes mellitusn (%)
Total n (%) 19 (6.8) 92 (33.1) 167 (60.1)
Ethnicity
Coloured 12 55 107
Black 6 33 55
Other 1 4 5
Age (years)* 27 (17–39) 33 (21–45) 32 (18–46)
Body mass index (kg/m2)* 26.4 (19–34) 34 (18–54) 36.9 (20–68)
Parity
0 6 8 (8.7) 25 (15.0)
1 7 30 (32.6) 45 (26.9)
2 6 22 (23.9) 43 (25.7)
≥ 3 0 32 (34.8) 54 (32.3)
Previous gestational diabetes mellitus N/A 13 (14.1) 18 (10.8)
Pre-existing maternal complications
Retinopathy 2 4 0
Renal lesion 1 6 7
Other 0 4 2
Previous pregnancy complications
Macrosomia 1 17 (18.5) 26 (15.6)
Miscarriage 4 23 (25.0) 45 (26.9)
Intrauterine death 0 6 (6.5) 20 (12.0)
Shoulder dystocia 0 3 (3.3) 4 (2.4)
Chronic hypertension 1 39 (42.4) 38 (22.8)
Pre-conception counselling 1 1 2
Booking gestation, (weeks)* 12.5 (6–28) 13 (5–34) n/a
Gestation at diagnosis of diabetes mellitus (weeks)* 28 (6–39)
Note: N/A = not applicable
*Median (range)
Table 2: Treatment modalities for gestational diabetes mellitus prior to delivery
Modalities n (%)
Lifestyle modification (diet and exercise) only 29 (17.4)
Lifestyle modification plus metformin 117 (70.1)
Lifestyle modification plus insulin 3 (1.8)
Lifestyle modification plus metformin plus insulin 18 (10.8)
Table 3: Maternal complications in women with gestational diabetes mellitus in relation to the mean haemboglobin A1c category for each patient
Complications, n ≤ 6.0% 6.1–7.0% 7.1–8.0% ≥ 8.0%
Total 47 74 29 10
Preterm birth 2 8 3 1
Hypertension* 9 10 11 1
Urinary tract infection 6 12 2 4
Diabetic ketoacidosis 0 0 0 1**
*Includes pre-eclampsia
**Gestational diabetes mellitus diagnosed at 12 weeks; probable undiagnosed pre-gestational diabetes mellitus
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(33.7%) patients used a sulphonylurea before pregnancy. Eleven 
patients required only metformin after sulphonylurea discontinu-
ation, while 20 patients needed insulin in addition to metformin. 
One patient presented at an advanced gestation (32  weeks) on 
combination therapy, with acceptable glucose control. She 
remained on metformin and glibenclamide. The final treatment 
modalities are shown in Table 4.
Important maternal complications according to the mean HbA1c 
category for each patient are shown in Table 5.
Seven cases with foetal anomalies were recorded, including 
central nervous system anomaly, i.e. Dandy-Walker syndrome; 
cardiac, i.e. ventricular septal defect and atrialventricular septal 
defect; skeletal, i.e. rhizomelic limb shortening, hemivertebra, 
spina bifida and tallipes equinovares; and renal, i.e. multicystic 
kidneys. The details of the five intrauterine deaths are shown in 
Table 6.
Eighty-four pregnancies reached viability. Of these 35 (41.7%) 
were delivered before, and 47 (55.9%) at, 38  weeks’ gestation. 
Induction of labour was performed in 41 (48.8%) viable pregnan-
cies and 50 (59.5%) infants were delivered by Caesarean section, 
of which 26 were elective operations. Two of the latter procedures 
were performed for suspected foetal macrosomia. The median 
(range) gestation at delivery was 37 weeks (25–39 weeks), and the 
median birthweight was 3 070 g (650–5 070 g). A birthweight of > 
4 kg was recorded in 8 (9.5%) infants, and there was one case of 
were admitted to the neonatal intensive care unit. Six (3.6%) babies 
were born with anomalies. There were no early neonatal deaths.
Pre-gestational type 2 diabetes mellitus
Most women were classified as obese according to BMI at their first 
pregnancy visit (booking). Nineteen (20.9%) were overweight, 31 
(34.1%) obese and 14 (15.4%) morbidly obese. The median SBP 
and DBP at booking were 130 mmHg (90–160 mmHg) and 80 
mmHg (50–100 mmHg), respectively. Of the 39 (42.4%) women 
with chronic hypertension, 6 (15.4%) were not on antihypertensive 
treatment. Other baseline values (median or range) were daily 
urinary protein excretion 140 mg (40–1 550 mg) and serum 
creatinine 56 μmol/l (28–153 μmol/l).
The median booking HbA1c was 7.5% (5.0–13.5%). The 25
th and 
75th percentiles were 6.8% and 9.2%, respectively. Pre-existing 
microvascular (renal and retinal) disease was documented in 10 
women. The retinal complications included three cases with 
proliferative, and one with non-proliferative, diabetic retinopathy. 
The median pre-delivery HbA1c lowered to 6.6% (4.4–10.4%). The 
25th and 75th percentiles were 5.9% and 7.5%, respectively.
Thirty-three (35.9%) patients with type 2 diabetes mellitus who 
had received oral hypoglycaemic agents only before pregnancy 
required the addition of insulin for optimal glucose control during 
pregnancy. Prandial insulin, in addition to the nocturnal dose of 
intermediate-acting insulin, was instituted in 10 cases. Thirty-one 
Table 4: Treatment modalities for type 2 diabetes mellitus prior to delivery




Metformin 81 (88.0) 86 (93.5)
Sulphonylurea* 31 (33.7) 1 (1.1)
Oral agents only 74 (80.4) 43 (46.7)
Insulin only 5 (5.4) 2 (2.2)
Oral agent, plus insulin 13 (14.1) 47 (51.1)
All cases with insulin 18 (19.6) 49 (53.3)
*Any sulphonylurea before pregnancy, glibenclamide during pregnancy
Table 5: Maternal complications in women with type 2 diabetes mellitus in relation to the mean haemboglobin A1c category for each patient
Maternal complications* ≤ 6.0% 6.1–7.0% 7.1–8% ≥ 8.0%
Total, n 25 25 20 9
Preterm birth** 1 7 6 2
Hypertension*** 2 4 3 1
Urinary tract infection 6 6 3 3
*Pre-delivery haemoglobin A1c was not available in 13 cases
**: Does not include hypertension
***Includes pre-eclampsia
Table 6: Intrauterine deaths in women with type 2 diabetes mellitus
Gestation Weight (g) Details
36 weeks, 0 days 3 080 Large for gestational age
36 weeks, 3 days 2 560 Defaulted from clinic for 10 weeks. Cause undetermined
37 weeks, 0 days 2 640 Placental abruption with pre-eclampsia
38 weeks, 2 days 2 580 Defaulted from clinic for 5 months. Cause undetermined
38 weeks, 2 days 3 350 No foetal movements for 3 days
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and the association with maternal hypertensive disorders were 
demonstrated to be independent of obesity; a metabolic 
abnormality almost invariably present in these patients, and which 
is able to contribute to these morbidities independently.3,4
The World Health Organization, which specifically concerns itself 
with health promotion in resource-limited countries, recently 
adopted the new IADPSG guidelines despite the expectation of 
increased patient numbers. Therefore, personnel in South African 
institutions that manage gestational diabetes mellitus should at 
least consider these new criteria as a gold standard and adapt 
practice pragmatically.
It is encouraging to note that the criteria used to formulate the 
Western Cape’s diabetes in pregnancy provincial guideline9 has 
further been supported by the most recent revision of the National 
Institute for Health and Care Excellence (NICE) guidelines.13 This 
document advocates a one-step approach with diagnostic thresh-
olds using fasting and two-hour values of 5.6  mmol/l and 
7.8 mmol/l, respectively. With the plethora of confusing diagnostic 
values for gestational diabetes mellitus, it should be noted that the 
NICE and Western Cape guidelines conform to the well-known, 
pre-diabetes mellitus thresholds in non-pregnant individuals. A 
lower fasting cut-off of 5.1mmol/l is proposed in the current 
IASDPG gold standard values in pregnancy.9
Because overt diabetes mellitus implies periconceptional dysglycaemia, 
and holds greater risks for the mother and foetus, it is important to 
detect undiagnosed pre-gestational (usually type 2) diabetes melli-
tus, often falsely regarded simply as gestational diabetes mellitus, as 
early as possible.11 The new proposed IADPSG guidelines emphasise 
that women at high risk of overt diabetes mellitus should be tested at 
the first opportunity, rather than waiting until between 24 and 
28 weeks, as often recommended, because of this (Figure 1).11
The current literature provides guidance on how to distinguish 
between these two conditions which have significantly different 
shoulder dystocia. A five-minute Apgar score < 7 was recorded in 
10 babies. One baby was admitted to the neonatal intensive care 
unit. There were no early neonatal deaths.
Discussion
The diagnosis, classification and management of diabetes 
mellitus in pregnancy continue to change. The results from this 
study will be used to discuss certain pertinent aspects. The first 
study aim was to document the contemporary numbers in our 
secondary or tertiary unit. The 285 cases seen every two weeks 
until delivery translated into a considerable workload. While 
pregnant women with pre-gestational diabetes mellitus require 
care at specialist level or higher, most of the women (60%) in this 
clinic had gestational diabetes mellitus which generally does not 
require specialist care. However, gestational diabetes mellitus 
with co-morbidities, such as morbid obesity (39%), chronic 
hypertension (23%), previous adverse outcomes or a previous 
Caesarean section, requires a higher level of care.
With obesity on the rise1,2 and diagnostic thresholds being 
lowered, rising patient numbers further burden resource-limited 
healthcare systems.10,11 While overt diabetes mellitus in pregnan-
cy is associated with significant adverse perinatal outcomes, the 
risks of hyperglycaemia less severe than overt diabetes mellitus 
are limited, and mostly relate to foetal overgrowth and maternal 
hypertensive risk.11
Recently, the International Association of Diabetes in Pregnancy 
Study Group (IADPSG) proposed more stringent diagnostic criteria, 
which unlike all previously proposed criteria, are based not only on 
the maternal risk of sustained dysglycaemia after pregnancy, but 
also on adverse pregnancy outcomes.11 However, because the ob-
servational HAPO study reported a continuum of risk, rather than 
an obvious threshold, units and administrators must determine 
their own screening policies by balancing the cost-effectiveness 
and treatment benefits of gestational diabetes mellitus.3,12 Impor-
tantly, significant risks of foetal overgrowth, foetal hyperinsulinaemia 
Figure 1: International Association for Diabetes and Pregnancy Study Groups protocol for the evaluation of diabetes mellitus in pregnancy.
Note: FBG: fasting blood glucose, HbA1c: haemoglobin A1c, OGTT: oral glucose tolerance test.
11
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Strategies to further improve outcomes include facilitating 
planned pregnancies with pre-conception counselling and 
optimal glycaemic control for pre-gestational diabetes mellitus 
and the prompt recognition of undiagnosed type 2 diabetes 
mellitus in pregnant women. The latter point is closely linked to 
our screening and diagnosis policy which is undergoing revision. 
Furthermore, close compliance with care is essential. Finally, 
because neonates from pregnancies complicated by diabetes 
mellitus suffer from higher rates of obesity and metabolic 
dysfunction later in life, attempts to break the vicious circle of 
metabolic imprinting through education and interventions are 
important.19
Conclusion
Pregnancies complicated by gestational and type 2 diabetes mellitus 
are increasing. It is important to distinguish between undiagnosed 
pre-gestational diabetes mellitus and gestational mellitus in the 
South African context. Lifestyle modification and metformin lower 
the need for insulin therapy substantially. Good results can be antici-
pated, despite the fact that both diabetes mellitus and associated 
morbidities pose management challenges. Optimal management of 
patients with diabetes mellitus in pregnancy would not only 
improve immediate maternal and foetal well-being, but might 
significantly impact on metabolic foetal imprinting, and thus 
hopefully reduce the present burden of metabolic sequelae in adult life.
Supplementary material
Supplementary material for this article can be accessed here 
http://dx.doi.org.10.1080/16089677.2015.1069015.
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risks. Approaches include timing, using fasting values or OGTT 
values diagnostic of diabetes mellitus in non-pregnant women, 
or recognising pathology specific to pregestational diabetes 
mellitus.11 If a pregnant woman, at any time in pregnancy, meets 
any of the diagnostic criteria for overt diabetes mellitus in 
non-pregnancy, she must be regarded as having pre-gestational 
and not “true” gestational diabetes mellitus.11
This is a fundamental change in our way of thinking, as traditionally, 
any degree of dysglycaemia diagnosed for the first time in pregnancy 
was referred to as gestational diabetes mellitus. It is not advocated 
that the HbA1c measurement is used to screen for gestational diabetes 
mellitus. However, internationally, its use is accepted in diagnosing 
pre-gestational diabetes mellitus.14 During our study, these distinguish-
ing characteristics were not strictly applied in early pregnancy. With a 
high prevalence of obesity and limited exposure to formal health care, 
cases of undiagnosed pregestational diabetics in pregnant women 
will occur. These considerations and findings in our study led to the 
deduction that the traditional definition of gestational diabetes mellitus 
needs to be revised to ensure appropriate patient care.
Another study aim was to evaluate the contributions of therapies. 
Lifestyle modification and insulin are well established, but recently 
two oral agents, metformin and glibenclamide, have gained promi-
nence.7,8 In our study, lifestyle modifications alone were sufficient in 
17% of gestational diabetes mellitus cases. This is low compared to 
the findings in the study by Crowther et al. (80%).5 One explanation is 
that resources are limited and the diet contains a high proportion of 
carbohydrates in this study population. Financial challenges limit the 
ability to fully embrace the proposed lifestyle changes. In addition, 
the low percentage of those controlled by lifestyle modification 
provides further evidence of undiagnosed cases of pre-gestational 
diabetes mellitus within the “traditional” gestational diabetes 
mellitus group.5
Metformin is a safe and well tolerated agent which reduces the 
need for insulin, decreases macrosomia and reduces Caesarean 
sections.15 As a result of using metformin in our study, 88% of 
women with gestational and 47% with type 2 diabetes mellitus 
did not require insulin. These results are similar to the metformin 
“success rate” of 79% reported by Silva et al., but better than those 
noted in the study by Rowan et al., in which 46% needed 
supplemental insulin.7,16 However, population characteristics and 
targets vary within studies. The “success rate” of glibenclamide 
and glyburide in gestational diabetes mellitus varies from 71–96%.8,16
The final study aim was to investigate certain specific outcomes. The 
decrease in HbA1c values during care for both groups was encouraging. 
Most deliveries occurred at 38  weeks’ gestation, with co-morbidities 
accounting for deviations, which supported the necessity of frequent 
follow-ups. After 20 weeks, the risk of intrauterine death in a large 
cohort of pregnant women with pre-gestational diabetes mellitus was 
reported by Tennant et al. to be more than four times greater than that 
in women without diabetes mellitus, with no difference found for types 
1 and 2 diabetes mellitus.17 There were seven intrauterine deaths, but 
no early neonatal deaths, in our study. In three cases, patients defaulted 
on keeping appointments for their visits, and at least one intrauterine 
death could have been prevented by induction at 38 weeks. Obesity 
and diabetes mellitus are well known associations of pre-eclampsia 
which complicated two intrauterine death cases. When compared to 
routine care, the Cochrane meta-analysis on treatment for gestational 
diabetes mellitus demonstrated a significant reduction in pre-eclamp-
sia and perinatal morbidity with intensive treatment, including the 
induction of labour.18
